The first PROTAC is approved: vepdegestrant in ESR1+ breast cancer

On May 1, 2026 the FDA approved vepdegestrant (VEPPANU, ARV-471), an oral estrogen-receptor degrader from Arvinas and Pfizer, for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer. It is the first PROTAC ever approved by a major regulator, which makes it a milestone for a whole modality, not just one more endocrine agent.

What makes a PROTAC different from a SERD

Conventional selective estrogen receptor degraders such as fulvestrant bind the receptor and destabilize it, nudging it toward degradation through induced conformational instability. The relationship is one-to-one: one drug molecule occupies one receptor.

A PROTAC is a bifunctional molecule. One end binds the estrogen receptor, a flexible linker bridges the middle, and the other end recruits an E3 ubiquitin ligase, in vepdegestrant's case cereblon. By forcing the receptor and the ligase into proximity, the PROTAC tags the receptor with ubiquitin and hands it to the proteasome. The drug molecule then releases and does it again. That catalytic, event-driven mechanism is the conceptual prize: deeper target depletion at lower drug exposure than an occupancy-driven binder can achieve, and a mechanism that does not depend on continuously saturating every receptor copy.

The VERITAC-2 data

Approval rested on VERITAC-2 (NCT05654623), a global randomized phase 3 trial comparing vepdegestrant monotherapy against fulvestrant in ER+/HER2- advanced breast cancer that had progressed on a CDK4/6 inhibitor plus endocrine therapy.

• ESR1-mutant population — vepdegestrant improved progression-free survival versus fulvestrant with a hazard ratio of 0.57 (P=.0001), alongside a higher objective response rate.
• Intent-to-treat population — the PFS benefit did not reach significance across all-comers, which is why the label is restricted to the ESR1-mutated subgroup rather than every ER+ patient.
• Overall survival — still immature at the time of approval.

The ESR1-mutant restriction is the clinically important detail. ESR1 mutations are a dominant driver of acquired resistance to aromatase inhibitors, and they are exactly the setting where deeper receptor degradation should pay off. The FDA cleared the drug roughly five weeks ahead of its June 5, 2026 PDUFA date.

Why this matters beyond breast cancer

Degraders solve a problem that occupancy inhibitors structurally cannot: you cannot second-site-mutate a binding pocket to escape a drug if the protein no longer exists. The resistance-via-pocket-mutation pattern that ends so many kinase-inhibitor programs (think EGFR C797S or BCR-ABL T315I) is far harder to pull off against a degrader. Vepdegestrant's approval is the proof point the field needed that the modality can clear the regulatory bar, and it de-risks the dozens of PROTAC programs now aimed at targets from BTK to KRAS to androgen receptor.

Try the docking yourself

A PROTAC still has to bind its target with a real small-molecule warhead, and that binding end is an ordinary molecular docking problem: dock the target-engaging fragment into the ligand-binding domain, then let the linker and E3 ligand do the recruiting. If your interest is the breast-cancer kinase axis, Open Studio and pick HER2 or PI3K-alpha from the target catalog to dock candidate ligands against the structures that sit downstream of ER signaling.

Liganx is molecular docking online: free, browser-based, and mutation aware, so you can compare wild-type and mutant pockets in the same run. If you want to try molecular docking on an oncology target without a local install, that is the fastest path. For more on why PROTACs break the usual drug-likeness rules, see our earlier post on PROTAC oral bioavailability.

Primary sources

• U.S. Food and Drug Administration. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer (May 2026). fda.gov
• Arvinas, Inc. Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer (press release, May 2026). ir.arvinas.com
• VERITAC-2: A Phase 3 Study of ARV-471 (PF-07850327) vs Fulvestrant in ER+/HER2- Advanced Breast Cancer. ClinicalTrials.gov NCT05654623